Medical Marijuana Use in HIV+ Patients Prospective Cohort Study (MMC-1)

This study is ongoing, but not recruiting participants.
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Mark Greenwald, PhD, Wayne State University Identifier:
First received: February 16, 2012
Last updated: April 26, 2016
Last verified: April 2016

The investigators are interested in understanding personal factors such as medical conditions and mental health, as well as social and economic factors, that influence marijuana (and other substance) use in HIV-positive patients.

Several alternative hypotheses will be evaluated in the proposed project:

  1. healthier patients may self-select marijuana use;
  2. marijuana use may be associated with consequences that create barriers to seeking healthcare;
  3. marijuana use may have medicinal value that reduces the need for such care.

HIV Positive
Marijuana Smoking

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients Prospective Cohort Study

Resource links provided by NLM:

Further study details as provided by Wayne State University:

Estimated Enrollment: 150
Study Start Date: February 2012
Estimated Study Completion Date: September 2016
Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Detailed Description:

The study will involve a total of 5 interviews with clinical research staff members, the total involvement will be for about 1 year.

The first interview will establish a baseline of current behaviors and health status; this will take about 3-4 hours. This interview will take place at the Tolan Park Medical Building, located at 3901 Chrysler Service Dr. The remaining 4 interviews - which will be shorter in length - will be conducted about 3, 6, 9, and 12 months after the baseline interview; each follow-up interview will take about 2 hours.The purpose of the 4 remaining interviews is to assess changes in behaviors and health status over time.

We will collect urine samples at each of the 5 interview sessions to assess health and illicit drug use.


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
HIV positive and marijuana using volunteers

Inclusion Criteria:

  • Participants will be patients in the HIV clinic.
  • Participants will have HIV.
  • Participants will sign a single consent form.
  • Participants will be marijuana users.

Exclusion Criteria:

  • Participants who test negative for marijuana will be excluded.
  • Volunteers who exhibit signs of drug intoxication or cognitive/mental impairment during the consent process will be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01536899

United States, Michigan
Wayne State University (HIV clinic, Tolan Park Medical Buiding)
Detroit, Michigan, United States, 48201
Sponsors and Collaborators
Wayne State University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Mark Greenwald, PhD Wayne State University
  More Information

Responsible Party: Mark Greenwald, PhD, Professor, Wayne State University Identifier: NCT01536899     History of Changes
Other Study ID Numbers: MMC-1  R01DA032678 
Study First Received: February 16, 2012
Last Updated: April 26, 2016
Health Authority: United States: Federal Government
United States: Institutional Review Board

Keywords provided by Wayne State University:
HIV positive
Medical Marijuana

Additional relevant MeSH terms:
HIV Seropositivity
Marijuana Abuse
Chemically-Induced Disorders
HIV Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Mental Disorders
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Substance-Related Disorders
Virus Diseases processed this record on May 26, 2016